Lucis announced it has raised $20 million in Series A funding led by Singular, with participation from General Catalyst, Y Combinator, and angel investors including Céline Lazorthes and Manu Lecomte. The company said the funding will support the expansion of its AI-powered preventive health platform across Europe and further development of its health companion application.
The new financing comes only four months after Lucis raised an $8 million seed round, bringing the company’s total funding to $28 million. Lucis explained that the growing demand for proactive and data-driven healthcare solutions has accelerated adoption of its platform.
Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis offers a preventive healthcare platform that analyzes more than 110 blood biomarkers spanning metabolic health, hormones, cardiovascular risk, inflammation, and nutrient levels. The company combines biomarker testing, longitudinal health tracking, and AI-powered analysis to deliver personalized recommendations around nutrition, supplementation, lifestyle changes, and follow-up testing.
Lucis said its recommendations are continuously refined using updated health data and are reviewed by physicians to help users understand what actions to take based on their biomarker results. The company currently employs a team of 20 across engineering, clinical operations, growth, and operations, while also working with a medical board and a network of physicians providing clinical oversight.
According to Lucis, its platform now serves more than 10,000 users across France, the UK, Ireland, and Portugal, and has processed more than one million biomarker tests. The company also said it has established partnerships with laboratory groups including Eurofins and Randox.
The company shared early user data indicating that among users who completed six-month follow-up testing, 75% improved at least three biomarkers without medication. Lucis also noted that more than 80% of users chose to retest, which the company said reflects ongoing engagement with personal health monitoring. In addition, Lucis stated that 99.9% of users initially tested had at least one biomarker outside optimal ranges, often without prior awareness.
Lucis believes Europe’s healthcare system remains heavily reactive despite increased awareness around preventive care and chronic disease prevention. The company said it aims to create a healthcare model focused on early detection, continuous monitoring, and personalized interventions before symptoms appear.
The company plans to expand into Spain, Germany, and Italy by the end of 2026 while continuing to invest in personalization, longitudinal monitoring, and clinical safety features.
KEY QUOTES:
“We’ve seen the devastating impact of late-stage diagnosis first-hand. The science is already there; what’s missing is a system designed to act before symptoms appear. This is why we built Lucis. By combining biomarker data and AI-driven clinical insights, we can catch what the system misses. Europe deserves a healthcare model that doesn’t wait for people to get sick. We are making prevention the default, rather than a privilege.”
Maxime Berthelot, Co-founder And CEO, Lucis
“Europe’s preventive health category will be won by platforms that unite clinical credibility with AI at scale. Lucis has moved with remarkable velocity, reaching 10,000 users in under a year, delivering measurable outcomes and building a compounding data advantage that sets the standard for the category. We see Lucis as a clear category winner in Europe and are excited to partner with the team as the product continues to evolve alongside customer needs.”
Jeremy Uzan, Co-Founder And GP, Singular
